Vaxcyte
PCVX
265 hedge funds and large institutions have $9.26B invested in Vaxcyte in 2024 Q2 according to their latest regulatory filings, with 38 funds opening new positions, 116 increasing their positions, 79 reducing their positions, and 23 closing their positions.
121% more call options, than puts
Call options by funds: $20.6M | Put options by funds: $9.3M
65% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 23
47% more repeat investments, than reductions
Existing positions increased: 116 | Existing positions reduced: 79
25% more funds holding in top 10
Funds holding in top 10: 12 → 15 (+3)
14% more capital invested
Capital invested by funds: $8.13B → $9.26B (+$1.13B)
6% more funds holding
Funds holding: 251 → 265 (+14)
2.79% more ownership
Funds ownership: 109.87% → 112.66% (+2.8%)
Top Buyers
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$81.3M |
| 2 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$32M |
| 3 |
CC
Commodore Capital
New York
|
+$30.3M |
| 4 |
BlackRock
New York
|
+$29.1M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
+$28.5M |
Top Sellers
| 1 |
DGM
Darwin Global Management
St. Helier,
Jersey
|
-$45.6M |
| 2 |
PBA
Paradigm Biocapital Advisors
New York
|
-$41.7M |
| 3 |
B
Braidwell
Stamford,
Connecticut
|
-$27.5M |
| 4 |
Pictet Asset Management
Carouge,
Switzerland
|
-$22.4M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$22.2M |
PCVX Hedge Fund Activity: Q2 2024 in Review
265 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Vaxcyte (PCVX) for Q2 2024, worth a combined $9.26B — up 14% from $8.13B a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new PCVX positions and 23 closed out — a net gain of 15 holders — while 116 added to existing stakes and 79 trimmed.
The largest buyer was Janus Henderson Group, adding an estimated $81.3M. The largest seller was Darwin Global Management, cutting an estimated $45.6M.
- 265 institutional investors held Vaxcyte (PCVX) as of Q2 2024, up from 251 in Q1 2024.
- Funds reported $9.26B of Vaxcyte stock for Q2 2024, up 14% quarter-over-quarter.
- 38 funds opened new Vaxcyte positions in Q2 2024 and 23 closed out, a net change of +15 holders.
- The largest Vaxcyte buyer in Q2 2024 was Janus Henderson Group, an estimated $81.3M added.
- The largest Vaxcyte seller in Q2 2024 was Darwin Global Management, an estimated $45.6M sold.
Based on aggregated 13F filings for Q2 2024.